台中港酒店親子飯店開箱+５大親子主題房

HEMLIBRA® (emicizumab | 合法藥品大搜索

HEMLIBRA® (emicizumab

LearnaboutHEMLIBRA®(emicizumab-kxwh),ahemophiliaAtreatmentapprovedforpeoplewithhemophiliaAwithorwithoutfactorVIIIinhibitors.

 HEMLIBRA® (emicizumab

What is the most important information I should know about HEMLIBRA?

HEMLIBRA increases the potential for your blood to clot. People who use activated prothrombin complex concentrate (aPCC; Feiba®) to treat breakthrough bleeds while taking HEMLIBRA may be at risk of serious side effects related to blood clots.

These serious side effects include: 

Thrombotic microangiopathy (TMA), a condition involving blood clots and injury to small blood  vessels that may cause harm to your kidneys, brain, and other organs  Blood clots (thrombotic events), which may form in blood vessels in your arm, leg, lung, or head  

Talk to your doctor about the signs and symptoms of these serious side effects, which can include: 

Confusion Stomach, chest, or back pain Weakness Nausea or vomiting ...

閱讀更多

Hemophilia emicizumab Emicizumab emicizumab acquired hemophilia Emicizumab mechanism HEMLIBRA emicizumab for the treatment of acquired hemophilia a Emicizumab nejm Roche Hemlibra emicizumab健保 Emicizumab hemlibra健保 emicizumab中文 Hemlibra Hemophilia emicizumab Emicizumab 台灣 hemlibra仿單 Roche hemlibra FEIBA NovoSeven Hemlibra hcp emicizumab acquired hemophilia Emicizumab mechanism HEMLIBRA emicizumab for the treatment of acquired hemophilia a Emicizumab nejm Roche Hemlibra 降尿酸藥物種類 景德製藥電話 hydrocortisone cream副作用 Triazolam 三唑侖藥效 shitan副作用 舒肉筋新錠一次幾顆 粉紅色止痛藥
Emicizumab | 合法藥品大搜索
Read More
Emicizumab for the treatment of acquired hemophilia A | 合法藥品大搜索
由 P Knoebl 著作 · 2021 · 被引用 18 次 — For hemostatic treatment, bypassing agents and human or porcine FVIII are currently standard of care. Emicizumab is a bispecific, FVIII-mimetic ... Read More
Model of Short | 合法藥品大搜索
由 ZY Zhou 著作 · 2020 · 被引用 2 次 — Background: Hemophilia A (HA) can result in bleeding events because of low or absent clotting factor VIII (FVIII). Read More
Emicizumab Prophylaxis in Hemophilia A with Inhibitors | 合法藥品大搜索
由 J Oldenburg 著作 · 2017 · 被引用 546 次 — Emicizumab prophylaxis was associated with a significantly lower rate of bleeding events than no prophylaxis among participants with ... Read More
Emicizumab for the treatment of acquired hemophilia A | 合法藥品大搜索
2021年1月21日 — Emicizumab is a bispecific, FVIII-mimetic therapeutic antibody that has considerably reduced the annualized bleeding rates in congenital ... Read More
Emicizumab for the treatment of haemophilia A | 合法藥品大搜索
由 M Franchini 著作 · 2019 · 被引用 32 次 — In a long-term primate model of acquired haemophilia A, the same authors showed that weekly subcutaneous doses of emicizumab (initially 4 mg/kg ... Read More
What is the role of emicizumab in the treatment of hemophilia A? | 合法藥品大搜索
2020年6月5日 — What is the role of emicizumab in the treatment of hemophilia A? ... Emicizumab is a first-in-class bispecific monoclonal antibody that performs ... Read More
Emicizumab Prophylaxis in Patients Who Have Hemophilia A ... | 合法藥品大搜索
由 J Mahlangu 著作 · 2018 · 被引用 300 次 — Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor ... Read More
HEMLIBRA® (emicizumab | 合法藥品大搜索
Learn about HEMLIBRA® (emicizumab-kxwh), a hemophilia A treatment approved for people with hemophilia A with or without factor VIII inhibitors. Read More
相關資訊整理

【第九凝血因子６００國際單位注射劑】預防及治療乙型血友病及缺乏第九凝血因子

藥品名稱:第九凝血因子６００國際單位注射劑許可證字號:衛署菌疫輸字第000425號許可證種類:菌　疫適應症:預防及治療乙型血友...

【抗血友病因子注射劑】Ａ型血友病（典型血友病）

藥品名稱:抗血友病因子注射劑許可證字號:衛署菌疫輸字第000142號許可證種類:菌　疫適應症:Ａ型血友病（典型血友病）劑型:藥...

【諾和第九因子注射劑1000 IU】12歲以上B型血友病(先天性第九凝血因子缺乏)病人的出血治療及預防。

藥品名稱:諾和第九因子注射劑1000IU許可證字號:衛部菌疫輸字第001130號許可證種類:菌　疫適應症:12歲以上B型血友病(先天性第...

【第九凝血因子１０００國際單位注射劑】預防及治療乙型血友病、預防及治療缺乏第九及第十凝血因子

藥品名稱:第九凝血因子１０００國際單位注射劑許可證字號:衛署菌疫輸字第000294號許可證種類:菌　疫適應症:預防及治療乙型血...

【愛必凝基因工程第九凝血因子注射劑1000國際單位/2000國際單位】適用於預防及治療B型血友病患者(先天性第九凝血因子缺乏症)之出血，包括接受外科手術時出血的控制與預防。

藥品名稱:愛必凝基因工程第九凝血因子注射劑1000國際單位/2000國際單位許可證字號:衛部菌疫輸字第001061號許可證種類:菌　疫...

【愛必凝基因工程第九凝血因子注射劑250國際單位】適用於預防及治療B型血友病患者(先天性第九凝血因子缺乏症)之出血，包括接受外科手術時出血的控制與預防。

藥品名稱:愛必凝基因工程第九凝血因子注射劑250國際單位許可證字號:衛部菌疫輸字第001059號許可證種類:菌　疫適應症:適用於...

【"百特" 抗血友病因子　５００　國際單位注射劑】治療Ａ型血友病。

藥品名稱:"百特"抗血友病因子　５００　國際單位注射劑許可證字號:衛署菌疫輸字第000605號許可證種類:菌　疫適應症:治療Ａ型...

【艾拉特凍晶注射劑 250IU】「治療與預防A 型血友病患者(先天性第八凝血因子缺乏)的出血。」說明:ELOCTATE不適用於治療溫韋伯氏病(von Willebrand disease)

藥品名稱:艾拉特凍晶注射劑250IU許可證字號:衛部菌疫輸字第001026號許可證種類:製　劑適應症:「治療與預防A型血友病患者(先...

【諾和第十三因子注射劑 2500IU】先天性缺乏第十三因子次單元A病患的常規出血預防治療。

藥品名稱:諾和第十三因子注射劑2500IU許可證字號:衛部菌疫輸字第001049號許可證種類:菌　疫適應症:先天性缺乏第十三因子次單...

【艾拉特凍晶注射劑 500IU】「治療與預防A 型血友病患者(先天性第八凝血因子缺乏)的出血。」說明:ELOCTATE不適用於治療溫韋伯氏病(von Willebrand disease)

藥品名稱:艾拉特凍晶注射劑500IU許可證字號:衛部菌疫輸字第001027號許可證種類:製　劑適應症:「治療與預防A型血友病患者(先...

【血甯博皮下注射劑150毫克/毫升】適用於帶有或未帶有第八凝血因子抗體的A型血友病（先天性第八凝血因子缺乏）病人之出血事件常規性預防。

藥品名稱:血甯博皮下注射劑150毫克/毫升許可證字號:衛部菌疫輸字第001087號許可證種類:菌　疫適應症:適用於帶有或未帶有第八...

【愛必凝基因工程第九凝血因子注射劑500國際單位】適用於預防及治療B型血友病患者(先天性第九凝血因子缺乏症)之出血，包括接受外科手術時出血的控制與預防。

藥品名稱:愛必凝基因工程第九凝血因子注射劑500國際單位許可證字號:衛部菌疫輸字第001060號許可證種類:菌　疫適應症:適用於...